SynthesisFrontiers in immunology2026
Antibody-based regimens targeting PD-1/PD-L1 and VEGF/VEGFR in advanced or metastatic NSCLC: a meta-analysis of RCTs.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-based regimens targeting programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) include conventional PD-1/PD-L1 inhibitors combined with anti-angiogenic monoclonal antibodies and PD-1/VEGF or PD-L1/VEGF bispecific antibodies, with or without chemotherapy. However, the clinical efficacy of these regimens in advanced or metastatic non-small cell lung cancer (NSCLC) remains unclear. This meta-analysis systematically evaluated their efficacy. Materials and methods: PubMed, EMBASE, Web of Science, ClinicalTrials.gov, and the Cochrane Library were searched to identify relevant randomized controlled trials (RCTs) published up to February 2026. The main outcomes analyzed were progression-free survival (PFS) and overall survival (OS), with the hazard ratio (HR) and 95% confidence interval (95%CI) used for statistical analysis. The study protocol was registered on PROSPERO (CRD420251126421). Results: Eleven RCTs were included in the analysis, with 4,426 participants. Antibody-based regimens targeting PD-1/PD-L1 and VEGF/VEGFR, with or without chemotherapy, were associated with better PFS (HR = 0.65, 95%CI: 0.57-0.75, p<0.001) and OS (HR = 0.79, 95%CI: 0.71-0.87, p<0.001) compared with the control regimen. For PFS, favorable subgroup estimates were observed in men (HR = 0.61), squamous histology (HR = 0.57), patients with liver metastases (HR = 0.49), those with higher PD-L1 expression (tumor proportion score (TPS)≥50%: HR = 0.65), those with epidermal growth factor receptor (EGFR) mutation (HR = 0.60). For OS, favorable subgroup estimates were observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS)=1 (HR = 0.80), men (HR = 0.80), smokers (HR = 0.82), those with liver metastases (HR = 0.57), those with PD-L1 TPS 1%-49% (HR = 0.67), and EGFR-mutant patients (HR = 0.80). Conclusion: Antibody-based regimens targeting PD-1/PD-L1 and VEGF/VEGFR improve prognosis in advanced or metastatic NSCLC, with potential variation in benefit across clinicopathological characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.